News
NEO
14.88
-1.33%
-0.20
Neogenomics Inc <NEO.OQ> expected to post breakeven results a share - Earnings Preview
Neogenomics Inc NEO.OQ expected to show a rise in quarterly revenue when it reports results on July 29 for the period ending June 30 2024. The company is expected to report a 10.2% increase in revenue to $161.847 million. Neogenomics expected to post breakeven results a share.
Reuters · 5h ago
Weekly Report: what happened at NEO last week (0715-0719)?
Weekly Report · 4d ago
NeoGenomics’s Growth and Resilience Affirm Buy Rating: Analyst Puneet Souda’s Perspective
TipRanks · 07/16 04:16
Weekly Report: what happened at NEO last week (0708-0712)?
Weekly Report · 07/15 11:04
Injunction again NeoGenomics over RaDaR assay affirmed by appeals court
Injunction again NeoGenomics over RaDaR assay affirmed by appeals court. A federal court in North Carolina has issued a preliminary injunction barring the company from manufacturing and selling its cancer test. The ruling sent NeoGenomic shares plunging 18% on Dec. 28.
Seeking Alpha · 07/12 15:24
Press Release: NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
Dow Jones · 07/09 11:07
Weekly Report: what happened at NEO last week (0701-0705)?
Weekly Report · 07/08 11:05
Weekly Report: what happened at NEO last week (0624-0628)?
Weekly Report · 07/01 11:06
Weekly Report: what happened at NEO last week (0617-0621)?
Weekly Report · 06/24 11:13
Weekly Report: what happened at NEO last week (0610-0614)?
Weekly Report · 06/17 11:05
BUZZ-SoftBank-backed Tempus AI jumps 18% in strong Nasdaq debut
SoftBank-backed Tempus AI jumps 18% in strong Nasdaq debut after IPO prices at high end of expectations. Shares of genetics testing firm jump as much as 17.9% to $43.64 in Nasdaq. Chicago-based Tempus valued at $6.60 bln at open.
Reuters · 06/14 16:10
BUZZ-SoftBank-backed Tempus AI jumps as much as 15% in Nasdaq debut
SoftBank-backed Tempus AI jumps as much as 15% in Nasdaq debut after IPO prices at high end of expectations. Shares of genetics testing firm jump 14.9% in its debut on Nasdaq. Chicago-based Tempus counts SoftBank among its prominent investors.
Reuters · 06/14 15:59
Weekly Report: what happened at NEO last week (0603-0607)?
Weekly Report · 06/10 11:07
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
GeneDx Holdings Corp. Focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing and Whole Genome sequencing are key revenue drivers, growing 96% in the first quarter. GeneDx uses whole exome and whole genome sequencing tests to identify rare diseases and accelerate drug discovery. Strong revenue growth, improving margin profile, and goal to achieve profitability by 2025 will contribute to a significant stock price advance.
Seeking Alpha · 06/06 11:00
UPDATE 2-SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO
SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO. The genetics-testing company is backed by Japanese tech investment firm SoftBank Group. Chicago-based Tempus is yet to be profitable. The company sells genomics diagnostics tests across oncology and other areas.
Reuters · 06/05 10:22
Weekly Report: what happened at NEO last week (0527-0531)?
Weekly Report · 06/03 11:09
NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO
Benzinga · 05/28 12:10
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
NeoGenomics, Inc. Will showcase its versatile lung solution at the American Society of Clinical Oncology conference in Chicago, May 31-June 4. The company's cancer genetics testing and information services company is a leading oncology testing services company. NeoGenomics will also present at the ASCO conference.
Barchart · 05/28 07:05
Weekly Report: what happened at NEO last week (0520-0524)?
Weekly Report · 05/27 11:14
Weekly Report: what happened at NEO last week (0513-0517)?
Weekly Report · 05/20 11:07
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.